SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                    FORM 8-K


                                 CURRENT REPORT

                   PURSUANT TO SECTION 13 OR 15(d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934
                          Date of Report: May 19, 1999



                                 MEDIMMUNE, INC.
             (Exact name of registrant as specified in its charter)



                         Commission File Number: 0-19131




           Delaware                                    52-1555759
        (State of Incorporation)                     (I.R.S. Employer
                               Identification No.)



              35 West Watkins Mill Road, Gaithersburg, MD 20878
              (Address of principal executive office (Zip Code)


      Registrant's telephone number, including area code (301) 417-0770


                No Exhibits are being filed with this report


CytoGam and RespiGam are  registered  trademarks of the Company and Synagis is a
trademark.

MEDIMMUNE, INC.
Current Report on Form 8-K


ITEM 5.  OTHER EVENTS

MedImmune, Inc. reported the information contained in the following press
release dated May 7, 1999:


FOR IMMEDIATE RELEASE
Contacts:
Mark E. Kaufmann                 
Director, Planning and Analysis
MedImmune, Inc.
301-417-0770 x321

William C. Roberts
Investor and Media Relations
MedImmune, Inc.
301-417-0770 x358

http://www.medimmune.com


    MEDIMMUNE  ANNOUNCES  PRESENTATION  OF  PHARMACOECONOMIC  DATA FOR SYNAGIS -
 RSV-Related Abstracts and Presentations at Pediatric Academic Societies'
                                    Meeting -

Gaithersburg,  MD, May 7, 1999 -- MedImmune,  Inc. (Nasdaq:MEDI) today announced
the  presentation of study results related to respiratory  syncytial virus (RSV)
this  week at the 1999  Pediatric  Academic  Societies'  Annual  Meeting  in San
Francisco.  Several  noteworthy  abstracts  relating  to  RSV  disease  and  its
prevention  were accepted for  publication or  presentation  at the  conference,
among which were: 1) an economic  study which showed that RSV  prophylaxis  with
Synagis   (palivizumab;   previously   identified   as  MEDI-493)   reduced  RSV
hospitalization  and its related costs, 2) a study showing the increasing  costs
associated  with RSV  pneumonia  in infants,  and 3) a  preclinical  study which
showed  that  prophylaxis  of  RSV  with  Synagis  in an  animal  model  reduced
RSV-associated  lung  inflammation,  which has been  associated  in humans  with
subsequent  development of asthma. RSV is the most common cause of pneumonia and
bronchiolitis   in  infants  and   children.   Abstracts   may  be  obtained  at
www.aps-spr.org/meetings/1999/abstracts.htm.

"The   pharmacoeconomic   data  presented  at  this  year's  Pediatric  Academic
Societies'  meeting  provides  important  new  information  about the  potential
benefits  to the health  care  system of  preventing  RSV  disease in  high-risk
patients,"  commented  Franklin H. Top, Jr., M.D.,  Executive Vice President and
Medical  Director  at  MedImmune.  "Additionally,  we are eager to  explore  the
connection  between RSV and asthma.  It is encouraging  to see that  prophylaxis
with Synagis in an animal model prevented some of the mechanisms associated with
asthma."

In the first study,  "Expected  Economic  Impact of Respiratory  Syncytial Virus
(RSV)  Prophylaxis,"  by Albert  Marchetti,  M.D.,  Vice  President  and Medical
Director of Health Economics Research,  et al., costs for protection and disease
were compared  including  Synagis-related  expenses and costs for in-patient and
out-patient  resources  to treat RSV  disease.  The study used  statistics  from
various sources  including  clinical trials conducted by MedImmune and published
epidemiological studies to assess the cost-benefit of Synagis.  Hospital billing
records  and public  sources  were  utilized  to  determine  charges  related to
prophylaxis  and medical  management of RSV  infection.  Results showed that the
economic impact of widespread use of Synagis ranged from an average  incremental
charge of $2,880 per patient to average savings per patient of $39,107.

"This is the first broad analysis of the cost-benefit of Synagis which takes
into account the full range of available data regarding Synagis-related
expenses and RSV infection treatment," commented Dr. Top.

The second study,  "The Rising Costs of RSV  Pneumonia in the Hospital:  US Data
from 1993-1994," was a retrospective  database  analysis to determine the trends
of costs,  length of stay, and severity associated with RSV pneumonia in infants
less than or equal to two  years of age.  The study  was  presented  by  Timothy
Howard,  President,  and Paul Stang,  Ph.D.,  Vice  President  and Chief Science
Officer,  of Galt  Associates,  a company that  provides  epidemiology  and drug
safety research and analysis  services.  Clinical and hospital resource use data
was derived from  discharge  abstracts  from  1993-1994  found in the Nationwide
Inpatient Sample (NIS) database,  a multi-state  integrated database coordinated
by the Agency for Health Care Policy and Research. The database contains patient
information from 6.5 million  in-patient stays annually from 900 hospitals in 17
states.  RSV pneumonia  accounted for 0.35 percent of all  discharges in infants
less than or equal to two years of age,  and both the number of  discharges  and
total  charges (in 1997  dollars) for RSV  pneumonia  rose from 1993 to 1994 (20
percent  increase in discharges from 15,826 to 18,965 and 30 percent increase in
total charges from $262 million to $341 million).  The mean charges of admission
for infants with  comorbidities  and RSV pneumonia,  for whom  prophylaxis  with
Synagis is now available, rose from $57,322 to $61,679 from 1993 to 1994.

"This study is the most recent and comprehensive analysis of costs to the
healthcare system of RSV pneumonia," added Dr. Top. "Quite frankly, the
increase in both discharges and total charges for RSV pneumonia surprised
us."

The third  presentation,  "Humanized  Monoclonal  Antibody  against  Respiratory
Syncytial Virus (Palivizumab)  Prevents RSV-induced  Neurogenic  Inflammation in
Rat  Airways,"  by Giovanni  Piedimonte  M.D et al.,  showed  that  prophylactic
administration of Synagis in an animal model prevented RSV-associated neurogenic
inflammation of the lower airway, which may be a component of asthma development
caused by viral  infection  in humans.  Rats  received  a single  dose of either
Synagis  or  a  placebo.   Prophylaxis  with  Synagis  reduced  neurogenic  lung
inflammation  by 61 percent  compared to the  placebo  control  (p=0.0005).  Dr.
Piedimonte is the Associate  Professor of Pediatrics,  Medicine and Pharmacology
and Director of Pediatric  Pulmonary  Division at the University of Miami School
of Medicine

"While this preliminary study is consistent with current  literature  suggesting
that RSV may be implicated  in the  development  of asthma,  this study does not
prove this hypothesis or that RSV prophylaxis may prevent asthma," said Dr. Top.
"MedImmune  intends to further study the potential role of Synagis in preventing
asthma in humans and the long-term problems associated with RSV infection."

Other noteworthy studies presented at the conference  included 1) "Evaluation of
Immunogenicity  and Safety in Children  Receiving  Palivizumab  (Synagis)  for a
Second  RSV  Season,"  by  Dr.  Donald  M.  Null,  M.D,  Director,  Division  of
Neonatology and Professor of Pediatrics at Allegheny General  Hospital,  et al.,
where Synagis was found to be safe and well tolerated,  and additional doses did
not result in  anti-Synagis  antibodies in this  population;  2)  "Evaluation of
Reconstituted Lyophilized Palivizumab (Synagis) given intravenously at 15 and 30
mg/kg.,"  by  Bernard  S.  Landry,   M.P.H.,   Assistant  Director  of  Clinical
Development   at  MedImmune,   et  al.,   which   suggested   that   intravenous
administration  of 15 and 30 mg/kg of  Synagis  using a 0.22  micron  filter was
generally safe and well-tolerated;  and 3) "Healthcare  Resource  Utilization by
Respiratory  Syncytial Virus Disease Patients," by Todd L. Wandstrat,  Pharm.D.,
Associate Professor, Department of Clinical Pharmacy and Family Medicine at West
Virginia  University,  et al., which was a 43 patient study  concluding that RSV
disease  causes  significant  in-patient  and  out-patient  healthcare  resource
utilization  and that  prophylaxis  with RespiGam  (Respiratory  Syncytial Virus
Immune Globulin Intravenous (Human)) reduced resource utilization.

Synagis is a humanized  monoclonal  antibody marketed by MedImmune in the United
States for the prevention of serious lower  respiratory  tract disease caused by
RSV in  pediatric  patients  at  high  risk  of RSV  disease  (please  see  full
prescribing    information    attached    and   at    ww.medimmune.com/products/
synagispi.htm).  Synagis is the first monoclonal antibody to be licensed for any
infectious disease.  Synagis is administered by intramuscular injection once per
month during  anticipated  periods of RSV  prevalence in the  community.  In the
Northern  Hemisphere,  the RSV season typically  commences in November and lasts
through April but it may begin earlier or persist later in certain  communities.
RSV is the most  common  cause of  pneumonia  and  bronchiolitis  in infants and
children. There are over 300,000 infants at risk of RSV in the United States. In
the U.S. alone,  over 90,000 children are hospitalized and the mortality rate of
hospitalized  infants with RSV infection of the lower respiratory tract is about
2 percent.  Sales of Synagis  through March 31,1999 for the 1998/1999 RSV season
totaled $226 million.  MedImmune  co-promotes  Synagis in the United States with
the Ross Products division of Abbott Laboratories (NYSE:ABT).

MedImmune, a biotechnology company located in Gaithersburg,  Maryland,  develops
and markets  products  that address  medical  needs in areas such as  infectious
disease,  transplantation medicine, autoimmune disorders and cancer. The Company
currently markets Synagis  (palivizumab),  RespiGam (Respiratory Syncytial Virus
Immune  Globulin  Intravenous  (Human)),  and  CytoGam  (Cytomegalovirus  Immune
Globulin  Intravenous  (Human)) through its  hospital-based  sales force and has
five new product candidates in clinical trials.

This announcement may contain,  in addition to historical  information,  certain
forward-looking statements that involve risks and uncertainties. Such statements
reflect management's current views and are based on certain assumptions.  Actual
results could differ materially from those currently  anticipated as a result of
a  number  of  factors,  including  risks  and  uncertainties  discussed  in the
Company's filings with the U.S.  Securities and Exchange  Commission.  MedImmune
cautions that RSV disease occurs primarily during the winter months; the Company
believes its operating results will continue to reflect that seasonality for the
foreseeable future.

                                    ####




(REGISTRANT)      MEDIMMUNE, INC.





BY (SIGNATURE)    /s/ David M. Mott
(NAME AND TITLE)  David M. Mott, Vice Chairman and Chief Financial Officer
(DATE)            May 19, 1999